Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | PLN-101095 |
| Trade Name | |
| Synonyms | PLN101095|PLN 101095 |
| Drug Descriptions |
PLN-101095 inhibits ITGB8 (integrin alphaVbeta8) and ITGB1 (integrin alphaVbeta1), which potentially results in decreased tumor growth (Journal for ImmunoTherapy of Cancer 2023;11, Suppl 1). |
| DrugClasses | |
| CAS Registry Number | NA |
| NCIT ID | NA |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Gemcitabine + Nab-paclitaxel + PLN-101095 | Gemcitabine Nab-paclitaxel PLN-101095 | 0 | 0 |
| Pembrolizumab + PLN-101095 | PLN-101095 Pembrolizumab | 0 | 1 |
| PLN-101095 | PLN-101095 | 0 | 1 |
| PLN-101095 + unspecified PD-1 antibody | PLN-101095 unspecified PD-1 antibody | 0 | 0 |